Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy.
#uroonc
#utuc
mitomycin-C
radical nephroureterectomy
robot-assisted
robotic nephroureterectomy
upper urinary tract urothelial carcinoma
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
9
7
2020
medline:
7
2
2021
entrez:
9
7
2020
Statut:
ppublish
Résumé
To assess the safety and feasibility of early single-dose mitomycin C (MMC) bladder instillation after robot-assisted radical nephroureterectomy (RARNU) at a tertiary kidney cancer centre. RARNU with bladder cuff excision and subsequent MMC bladder instillation to reduce recurrence risk is the 'gold standard' for high-risk upper urinary tract urothelial carcinoma (UUTUC). We adapted a RARNU technique with precise distal ureteric dissection, bladder cuff excision and watertight bladder closure. We retrospectively reviewed all patients undergoing RARNU for UUTUC at our centre performed as a standardised transperitoneal procedure comprising of: bladder cuff excision, two-layer watertight closure and intraoperative bladder leak test; without re-docking/re-positioning of the robotic surgical system. Patient demographics, the timing of MMC instillation, adverse events (surgical and potentially MMC-related) and length of stay (LOS) were assessed according to the Clavien-Dindo classification. A total of 69 patients underwent a RARNU with instillation of MMC. The median (interquartile range [IQR]) age was 70 (62-78) years. The median (IQR) day of MMC instillation was 2 (1-3) days and the median (IQR) LOS was 2 (2-4) days, with urethral catheter removal on day of discharge in all cases. Only Grade I Clavien-Dindo complications occurred in seven patients (10%); five had ileus, one a wound infection and one a self-limiting delirium, all managed conservatively. No adverse events potentially related to MMC instillation were noted within 30 days postoperatively. The use of intravesical MMC instillation given in the immediate postoperative period appears feasible and safe in patients undergoing RARNU with intraoperative confirmation of a water-tight closure ensuring early catheter-free discharge, with no significant adverse events. The potential reduction in intravesical recurrence in patients receiving early MMC needs to be assessed with longitudinal follow-up studies.
Substances chimiques
Antibiotics, Antineoplastic
0
Mitomycin
50SG953SK6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
739-744Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.
Références
Roupret M, Babjuk M, Comperat E et al. European Association Of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 2018; 73: 111-22
Xylinas E, Rink M, Margulis V et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol 2012; 61: 1069-70
Chen MK, Ye YL, Zhou FJ et al. Clipping the extremity of ureter prior to nephroureterectomy is effective in preventing subsequent bladder recurrence after upper urinary tract urothelial carcinoma. Chin Med J (Engl) 2012; 125: 3821-6
Yoo SH, Jeong CW, Kwak C, Kim HH, Choo MS, Ku JH. Intravesical chemotherapy after radical nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and network meta-analysis. J Clin Med 2019; 8: 1059
Hwang EC, Sathianathen NJ, Jung JH, Kim MH, Dahm P, Risk MC. Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma. Cochrane Database Syst Rev 2019; 5: CD013160
O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of O. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011; 60: 703-10
Ito A, Shintaku I, Satoh M et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013; 31: 1422-7
Bosschieter J, Nieuwenhuijzen JA, van Ginkel T et al. Value of an immediate intravesical instillation of Mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol 2018; 73: 226-32
Noennig B, Bozorgmehri S, Terry R, Otto B, Su LM, Crispen PL. Evaluation of intraoperative versus postoperative adjuvant Mitomycin C with nephroureterectomy for urothelial carcinoma of the upper urinary tract. Bladder Cancer 2018; 4: 389-94
Ni S, Tao W, Chen Q et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012; 61: 1142-53
Badani KK, Rothberg MB, Bergman A et al. Robot-assisted nephroureterectomy and bladder cuff excision without patient or robot repositioning: description of modified port placement and technique. J Laparoendosc Adv Surg Tech A 2014; 24: 647-50
Filson CP, Montgomery JS, Dailey SM et al. Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urol Oncol 2014; 32: 40.e1-8
Nieuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol 2003; 43: 711-2
Lim D, Izawa JI, Middlebrook P, Chin JL. Bladder perforation after immediate postoperative intravesical instillation of mitomycin C. Can Urol Assoc J 2010; 4: E1-3
Kurzer E, Leveillee RJ, Bird VG. Combining hand assisted laparoscopic nephroureterectomy with cystoscopic circumferential excision of the distal ureter without primary closure of the bladder cuff-is it safe? J Urol 2006; 175: 63-7
Gkougkousis EG, Mellon JK, Griffiths TR. Management of the distal ureter during nephroureterectomy for upper urinary tract transitional cell carcinoma: a review. Urol Int 2010; 85: 249-56
Chiang PH, Luo HL, Chen YT, Kang CH, Chuang YC, Lee WC. Is hand-assisted retroperitoneoscopic nephroureterectomy better than transurethral bladder cuff incision-assisted nephroureterectomy? J Endourol 2011; 25: 1307-13
Peyronnet B, Seisen T, Dominguez-Escrig JL et al. Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an european association of urology guidelines systematic review. Eur Urol Focus 2019; 5: 205-23
Pathak RA, Hemal AK. Techniques and outcomes of robot-assisted nephro-ureterectomy for upper tract urothelial carcinoma. Eur Urol Focus 2018; 4: 657-61
Kieves NR, Krebs AI. Comparison of leak pressures for single-layer simple continuous suture pattern for cystotomy closure using barbed and monofilament suture material in an ex vivo canine model. Vet Surg 2017; 46: 412-6
Gozen AS, Arslan M, Schulze M, Rassweiler J. Comparison of laparoscopic closure of the bladder with barbed polyglyconate versus polyglactin suture material in the pig bladder model: an experimental in vitro study. J Endourol 2012; 26: 732-6
Aboumohamed AA, Krane LS, Hemal AK. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma. J Urol 2015; 194: 1561-6
Veccia A, Antonelli A, Francavilla S et al. Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases. World J Urol 2020; 38: 845-52
Campi R, Cotte J, Sessa F et al. Robotic radical nephroureterectomy and segmental ureterectomy for upper tract urothelial carcinoma: a multi-institutional experience. World J Urol 2019; 37: 2303-11